Antiangiogenic therapy in leukemia

Acta Haematologica

Volumn 106, Issue 4, 2001, Pages 190-207

  Thomas, Deborah A ^a   Giles, Francis J ^a   Cortes, Jorge ^a   Albitar, Maher ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Leukemia; Vascular endothelial growth factor

Indexed keywords

1 778123; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; ABT 657; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANU 145156 E; ATRASENTAN; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CILENGITIDE; COMBRETASTATIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 12; L 778123; LONAFARNIB; MARIMASTAT; MM 1270; MONOCLONAL ANTIBODY LM 609; PENICILLAMINE; PRINOMASTAT; R 11577; REBIMASTAT; SEMAXANIB; SQUALAMINE; TANOMASTAT; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; ZK 22584;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CANCER CELL; CELL ACTIVATION; CELL CLONE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE MARKER; DRUG DEVELOPMENT; DRUG MONITORING; ENDOTHELIUM CELL; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEOVASCULARIZATION (PATHOLOGY); NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BONE MARROW; CLINICAL TRIALS; ENDOTHELIAL GROWTH FACTORS; HUMANS; LEUKEMIA; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035706444     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046616     Document Type: Article

References (176)

1. Tumor angiogenesis: Therapeutic complications
2. Angiogenesis in cancer, vascular, rheumatoid, and other disease
3. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
4. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
5. Death to a blood vessel, death to a tumor
6. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
7. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
8. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma
9. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
10. Angiogenesis and angiogenic mediators in haematological malignancies
11. Angiogenesis: Regulators and clinical applications
12. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells
13. Plasminogen activators and matrix metalloproteinases in angiogenesis
14. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
15. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
16. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation
17. Cutaneous wound healing
18. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
19. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
20. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3
21. The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing
22. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?
23. Factors promoting tumor angiogenesis
24. Clinical applications of angiogenic growth factors and their inhibitors
25. Angiogenesis and cancer control: From concept to therapeutic trial
26. Angiogenesis inhibitors
27. Angiogenesis inhibitors. New agents in cancer therapy
28. Vascular targeting - A new approach to the therapy of solid tumors
29. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
30. Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
31. Relation of neovascularization to metastasis of non-small-cell lung cancer
32. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
33. Tumor vascularity and basement membrane structure as prognostic factors in T1-2M0 prostatic adenocarcinoma
34. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma
35. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
36. Tumor angiogenesis correlates with lymph node metastasis in invasive bladder cancer
37. Expression of vascular endothelial cell growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
38. Extent of tumor vascularization correlates with the prognosis and hematogenous metastasis in gastric carcinomas
39. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma
40. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
41. CD31: An immunospecific marker for endothelial differentiation in human neoplasms
42. CD34: A review
43. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
44. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
45. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients
46. Pro-angiogenic cytokine pathways in acute lymphoblastic leukemia
47. Human acute lymphoblastic leukemia promotes angiogenesis in vivo: Pre-clinical models to develop targeted intervention
48. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
49. Evidence of increased angiogenesis in patients with acute myeloid leukemia
50. Angiogenesis in acute myeloid leukemia
51. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
52. Clinical relevance of vascular endothelial growth factor (VEGF) receptors 1 and 2 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
53. Clinical relevance of plasma endostatin levels in patients with acute myeloid leukemia or myelodysplastic syndrome
54. Angiogenesis in myelodysplastic syndromes
55. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
56. Prognostic significance of VEGF protein levels in the bone marrow of patients with chronic myeloid leukemia
57. Clinical relevance of Flk1/KDR (VEGF-R2) and (VEGF-R1) proteins in chronic myelogenous leukemia (CML)
58. Prognostic significance of Tie-1 protein expression in the bone marrow of patients with chronic myeloid leukemia
59. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
60. Elevated VEGF serum levels in idiopathic myelofibrosis
61. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia
62. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia
63. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukemia
64. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
65. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia
66. Implication of transforming growth factor beta in bone marrow fibrosis and myelosuppression in hairy cell leukemia
67. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia
68. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
69. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
70. Prognostic value of bone marrow angiogenesis in multiple myeloma
71. Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44
72. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of multiple myeloma
73. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
74. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphoma
75. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
76. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease
77. A high pretreatment serum basic-fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
78. Differential expression of transforming growth factor-α, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia
79. Clinical implications of circulating angiogenic factors in cancer patients
80. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
81. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
82. Angiogenic factors are hematopoietic growth factors and vice versa
83. The thin red line: Angiogenesis in normal and malignant hematopoiesis
84. Basic fibroblast growth factor stimulates myelopoiesis in long-term human bone marrow cultures
85. Tumor necrosis factor α and angiogenesis
86. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
87. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis
88. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
89. Vascular endothelial growth factor and its receptors in hematopoietic malignancies
90. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
91. Expression of basic fibroblast growth factor (b-FGF) and FGF-receptors in human leukemia cells
92. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis
93. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
94. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density in bone marrow biopsies
95. Bone marrow microvascular. Structure and function
96. The microcirculation of the bone marrow
97. Structure of the marrow
98. Endothelial cell embryology and growth
99. Long-term culture of human bone marrow. I. Characterization of adherent cells in flow cytometry
100. Vascular networks within the stroma of human long-term bone marrow cultures
101. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
102. The broad spectrum of cytokine gene expression by myoid cells from the human marrow microenvironment
103. Characterization of the 5q-breakpoint in an acute nonlymphocytic leukemia patient using pulsed-field gel electrophoresis
104. Human osteoblasts support human hematopoietic progenitor cells in in vitro bone marrow cultures
105. Peroxisome proliferator-activated receptor-γ(PPAR-γ) expression by bone marrow endothelium reveals a potential target for therapeutic intervention in acute lymphoblastic leukemia
106. De novo angiogenesis confers a selective advantage to leukemia cells through contact-dependent maintenance of anti-apoptotic gene expression
107. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia
108. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor
109. Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells
110. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
111. Expression of tie receptor tyrosine kinase in human leukemia cell lines
112. Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells
113. The tie receptor kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells
114. Chemotherapy targeted to tumor vasculature
115. Targeting tumor vasculature with homing peptides from phage display
116. Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD)
117. Requirement of vascular integrin alpha v beta 3 for angiogenesis
118. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
119. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
120. Longitudinal analysis of angiogenic factors and vascularity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
121. Thalidomide and thrombosis
122. Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi
123. Quantitative angiogenesis assays: Progress and problems
124. The preclinical evaluation of angiogenesis inhibitors
125. Redefining the target: Chemotherapeutics as antiangiogenics
126. Antiangiogenic potential of camptothecin and topotecan
127. Inhibition of angiogenesis by anthracyclines and titanocene dichloride
128. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin
129. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis
130. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process
131. Antiangiogenesis is produced by nontoxic doses of vinblastine
132. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma
133. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
134. Regulation of neoplastic angiogenesis
135. Interferon-α-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on the optimization of biologic dose and schedule
136. Treatment of hairy cell leukemia with recombinant alpha-interferon
137. Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients
138. Interferon-α restores normal β-1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia
139. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
140. Inhibition of angiogenesis in vivo by interleukin 12
141. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12
142. Thalidomide is an inhibitor of angiogenesis
143. Effects of thalidomide and related metabolites in a mouse corneal mode of neovascularization
144. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
145. Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation
146. Binding of thalidomide to 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor production
147. Antitumor activity of thalidomide in refractory multiple myeloma
148. Thalidomide (T) in the management of multiple myeloma (MM): The Arkansas experience in > 300 patients (Pts) with single agent (SA) and combination therapy (CT)
149. Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders
150. Addition of thalidomide (T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS
151. Current role of thalidomide in cancer treatment
152. Encouraging improvement in cytopenias of patients with myelodysplastic syndromes (MDS) with thalidomide
153. Biologic determinants of clinical response to thalidomide in myelodysplasia
154. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
155. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
156. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
157. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
158. A phase II study with SU5416 in patients with C-kit positive AML
159. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients with metastatic cancer
160. The contributions of cyclooxygenase-2 to tumor angiogenesis
161. Cyclooxygenase inhibitors - Current status and future prospects
162. Molecular pathology of cyclooxygenase-2 in neoplasia
163. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
164. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix
165. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470
166. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study
167. Angiogenesis inhibitor TNP-470: Cytotoxic effects on human neoplastic cell lines
168. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies
169. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects
170. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
171. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown
172. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice
173. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
174. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate
175. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach
176. Progress in antiangiogenic gene therapy of cancer